MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202621059385 A) filed by Prof. Pallavi Rahul Kaple on May 10, 2026, for A Pharmaceutical Cochleate Composition Comprising Cabozantinib And Process For Its Manufacture.
Inventors include Ms. Janhvi Chaskar; Dr. Shreeya Belwalkar; Ms. Shradha Todkar; Ms. Pratiksha More; Ms. Dipali Kamble; Ms. Supriya Chopade; Rushikesh Kuldharan; Dnyanyshwar Jadhav; Rushikesh Tare; and Vijay Gade.
The application for the patent was published on July 10, 2026, under issue no. 28/2026.
Abstract: The present invention relates to the cabozantinib-loaded cochleate drug delivery system intended for improved therapeutic performance in the treatment of hepatocellular carcinoma. Cabozantinib is a multi-targeted tyrosine kinase inhibitor widely used in liver cancer therapy; however, its clinical effectiveness is limited by poor solubility, systemic adverse effects, and variability in bioavailability. The invention provides a lipid-based cochleate formulation prepared using an ethanol injection method followed by calcium ion–mediated cochleate formation to enhance drug encapsulation and stability. The formulation was optimized using a factorial design approach and evaluated for physicochemical parameters including particle size, zeta potential, polydispersity index, morphology, entrapment efficiency, and drug content. Structural confirmation of cochleate formation was performed using scanning electron microscopy, FTIR spectroscopy, and differential scanning calorimetry. The optimized formulation exhibited high entrapment efficiency and controlled in-vitro drug release over an extended period. Further, cytotoxic evaluation against hepatocellular carcinoma HepG2 cell lines demonstrated promising anticancer activity of the developed cochleate formulation. The invention therefore provides a stable and effective cochleate-based carrier system for Cabozantinib with improved release characteristics and therapeutic applicability, representing a potential advancement in targeted lipid-based drug delivery for hepatocellular carcinoma management.
Disclaimer: Curated by HT Syndication.
